Mutation patterns of the reverse transcriptase genes in HIV-1 infected patients receiving combinations of nucleoside and non nucleoside inhibitors

International Journal of Antimicrobial Agents

Volumn 22, Issue 4, 2003, Pages 388-394

  Re, Maria Carla ^a   Bon, I ^a   Monari, P ^a   Borderi, M ^a   Gibellini, D ^a   Schiavone, P ^a   Vitone, F ^a   Chiodo, F ^a   La Placa, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

HIV 1; Mutation patterns; Reverse transcriptase genes

Indexed keywords

LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BACTERIAL GENETICS; BACTERIUM DETECTION; CODON; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MUTATIONAL ANALYSIS; PLASMA; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION;

EID: 0141792566     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00082-7     Document Type: Article

References (36)

1. Lukashov V.V., de Ronde A., de Jong J.J., Goudsmit J. Epidemiology of HIV-1 and emerging problems. Int. J. Antimicrob. Agents. 16:2000;463-466.
2. Manfredi R. Evolution of HIV disease in the third millennium: clinical and related economic issues. Int. J. Antimicrob. Agents. 19:2002;251-253.
3. Staszewski S., Morales-Ramirez K.T., Tashima A. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. New Engl. J. Med. 341:1999;1865.
4. Cheeseman S.H., Havlir M.M., McLaughlin T.C. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 8:1995;141-151.
5. Montaner J.S., Reiss P., Cooper D., et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. J. Am. Med. Assoc. 279:1998;930-937.
6. Lee L.M., Henderson D.K. Emerging viral infections. Curr. Opin. Infect. Dis. 14:2001;467-480.
7. Brinkman K., Smeitink J.A., Romijn J.A., Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 354:1999;1112-1115.
8. Serious adverse events attribute to nevirapine regimens by post exposure prophylaxis after HIV exposures: worldwide 1997-2000. Morb. Mortal. Wkly. Rep. 49:2001;1153-1156.
9. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 271:1996;1582-1586.
10. Mansky L.M., Temin H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:1995;5087-5094.
11. Perez-Alvarez L., Villahermosa M.L., Cuevas M.T., et al. Single- and multidrug resistance mutations to reverse transcriptase and protease inhibitors: human immunodeficiency virus type 1-infected patients from two geographical areas in Spain. Spanish Groups for Antiretroviral Resistance Studies. J. Hum. Virol. 3:2000;150-156.
12. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489.
13. Manfredi R., Chiodo F. Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease. Int. J. Antimicrob. Agents. 17:2001;511-516.
14. Moyle G.J., Gazzard B.G., Cooper D.A., Gatell J. Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs. 55:1998;383-404.
15. Clevenbergh P., Durant J., Halfon P., et al. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: week 48 follow-up. Antiviral Ther. 5:2000;65-70.
16. Baxter J.D., Mayers D.L., Wentworth D.N., et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 14:2000;F83-F93.
17. Re M.C., Monari P., Bon I., et al. Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients. BMC Microbiol. 1:2001;30-36.
18. Re M.C., Monari P., Bon I., et al. Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz. Int J Antimicrob Agents. 20:2002;223-226.
19. Re M.C., Borderi M., Monari P., et al. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a cohort of Italian HIV-1 seropositive patients extensively treated with antiretroviral drugs. Int. J. Antimicrob. Agents. 18:2001;519-523.
20. Gallo R.C. New concepts for future control of HIV derived from studies of pathogenesis. Int. J. Antimicrob. Agents. 16:2000;421-423.
21. Carpenter C.C., Cooper D.A., Fischl M.A., et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA Panel. J. Am. Med. Assoc. 283:2000;381-390.
22. Closet B, Menendez-Arias L, Ruiz L, et al., Guide to management of HIV drugs and pharmacokinetics of antiretroviral therapy, 2nd ed., Editorial TAISA S.I. Provenca, Barcelona, 2002.
23. Maeda Y., Venzon D.Y., Mitsuya H. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177:1998;1207-1213.
24. DHHS guidelines for the use of antiretroviral agents in HIV-Infected Adults and Adolescent http://www.iapac.org .
25. D'Aquila R. Incorporating antiretroviral resistance testing into clinical practice. A new standard of care in the management of HIV disease (http://www.visgen.com/clinical_Science/The lybrary/HIV/Trugene_Monograph_6191pdfA).
26. Yahi N., Tamalet C., Tourres C., et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. Clin. Microbiol. 37:1999;4099-4106.
27. Cleland A., Watson H.G., Robertson P., Ludlam C.A., Brown A.J. Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 12:1996;6-18.
28. Hooker D.J., Tachedjian G., Solomon A.E., et al. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J. Virol. 70:1996;8010-8018.
29. Iversen A.K., Shafer R.W., Wehrly K., et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1996;1086-1090.
30. Kavlick M.F., Wyvill K., Yarchoan R., Mitsuya H. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J. Infect. Dis. 98:1998;1506-1513.
31. Schmit J.C., Van Laethem K., Ruiz L., et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS. 12:1998;2007-2015.
32. Shirasaka T., Kavlick M.F., Ueno T., et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA. 92:1995;2398-2402.
33. Tamalet C., Yahi N., Tourres C., et al. Multidrug resistance genotypes (insertions in the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse transcriptase from extensively treated patients: incidence and association with other resistance mutations. Virology. 270:2000;310-316.
34. Larder B.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 246:1989;1155-1158.
35. Hirsch M.S., Brun-Vezinet F., D'Aquila R.T., et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society - USA Panel. J. Am. Med. Assoc. 283:2000;2417-2426.
36. Re M.C., Monari P., Borderi M., et al. Presence of genotypic resistance to anti-retroviral drugs in a cohort of therapy naive HIV-1 infected Italian patients. J. Acquired Immune Defic. Syndr. 27:2001;315-316.